NCT07219927Recruiting
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 22 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 9 Jun 2025
- Start date
- 31 Mar 2025
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Diseases
- Parkinson disease
- NCT number
- NCT07219927
What you commit to
- Study type: Observational
- Planned participants: 120
- From 31 Mar 2025 to the primary completion date, 1 Aug 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant use of ONAPGO™ with 5-HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) or alosetron.
Lab values
- Known hypersensitivity to apomorphine or to excipients of ONAPGO™, including sulfite (e.g., sodium metabisulfite).
Other
- Did not receive a prescription for ONAPGO™.
- Prescribed ONAPGO™, but the HCP/Investigator determines the participant should not participate in this observational study.
Who the study is looking for
- Participant has received a prescription for ONAPGO™ according to the standard of care.
- Participant has opted into receiving support services from the Clinical Nurse Navigator (CNN), a registered nurse specially trained to work with persons with Parkinson's disease, as noted on the Prescription Enrollment Form.
- The HCP/Investigator determines the participant is an appropriate study participant.
- Participant is able and willing to provide informed consent (or informed assent form \[IAF\], as applicable) and signs the consent form on the Enrollment Day.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Parkinson's Disease and Movement Disorders Center - Orange County (South) Coordinator of this site? Confirm its status | Aliso Viejo | United States | Recruiting |
| Parkinson's Disease & Movement Disorders Center of Boca Raton Coordinator of this site? Confirm its status | Boca Raton | United States | Recruiting |
| Parkinson's Disease and Movement Disorders Center - Long Island Coordinator of this site? Confirm its status | Commack | United States | Recruiting |
| Parkinson's Disease and Movement Disorders Center - Orange County (North) Coordinator of this site? Confirm its status | Irvine | United States | Recruiting |
| Parkinson?s Research Centers of America ? Palo Alto Coordinator of this site? Confirm its status | Palo Alto | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.